Immunome (NASDAQ:IMNM) Shares Gap Down to $15.61

Immunome, Inc. (NASDAQ:IMNM)’s share price gapped down before the market opened on Tuesday . The stock had previously closed at $15.61, but opened at $15.20. Immunome shares last traded at $15.17, with a volume of 66,247 shares trading hands.

Wall Street Analysts Forecast Growth

IMNM has been the topic of a number of research analyst reports. Wedbush reissued an “outperform” rating and issued a $33.00 price target on shares of Immunome in a report on Tuesday. Leerink Partnrs restated an “outperform” rating on shares of Immunome in a research note on Monday, January 29th. Guggenheim began coverage on Immunome in a research note on Monday, April 15th. They issued a “buy” rating and a $35.00 price objective on the stock. SVB Leerink began coverage on Immunome in a research note on Monday, January 29th. They issued an “outperform” rating and a $30.00 target price on the stock. Finally, JPMorgan Chase & Co. started coverage on Immunome in a research note on Tuesday, April 30th. They set an “overweight” rating and a $24.00 price target for the company. Six research analysts have rated the stock with a buy rating, According to MarketBeat.com, Immunome currently has an average rating of “Buy” and an average target price of $30.50.

Immunome Trading Down 2.7 %

The firm has a market cap of $863.18 million, a P/E ratio of -1.91 and a beta of 1.87. The business’s fifty day simple moving average is $19.54 and its 200-day simple moving average is $15.73.

Immunome (NASDAQ:IMNM) last released its quarterly earnings data on Thursday, March 28th. The company reported ($0.54) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.28) by ($0.26). The company had revenue of $3.83 million for the quarter, compared to the consensus estimate of $3.40 million. Immunome had a negative net margin of 761.92% and a negative return on equity of 69.74%. As a group, research analysts expect that Immunome, Inc. will post -1.91 earnings per share for the current fiscal year.

Hedge Funds Weigh In On Immunome

Several hedge funds and other institutional investors have recently added to or reduced their stakes in IMNM. Avidity Partners Management LP purchased a new stake in shares of Immunome in the 4th quarter valued at about $14,268,000. Price T Rowe Associates Inc. MD lifted its position in Immunome by 113.6% during the first quarter. Price T Rowe Associates Inc. MD now owns 2,245,673 shares of the company’s stock valued at $55,425,000 after purchasing an additional 1,194,451 shares during the last quarter. Redmile Group LLC increased its holdings in shares of Immunome by 26.0% in the 1st quarter. Redmile Group LLC now owns 4,889,554 shares of the company’s stock worth $120,674,000 after buying an additional 1,010,139 shares during the last quarter. Lord Abbett & CO. LLC bought a new position in Immunome in the first quarter valued at $10,994,000. Finally, Vanguard Group Inc. raised its holdings in shares of Immunome by 16.1% during the 1st quarter. Vanguard Group Inc. now owns 2,019,738 shares of the company’s stock valued at $49,847,000 after buying an additional 279,712 shares in the last quarter. 44.58% of the stock is currently owned by hedge funds and other institutional investors.

Immunome Company Profile

Immunome, Inc, a biotechnology company, develops targeted cancer therapies. The company's clinical asset comprises AL102, an investigational gamma secretase inhibitor currently in evaluation in a Phase 3 trial for the treatment of desmoid tumors; and preclinical assets consist of IM-1021, a receptor tyrosine kinase-like orphan receptor 1 and antibody-drug conjugates, as well as IM-3050, a fibroblast activation protein targeted radioligand therapy; and IM-4320, an anti-IL-38 immunotherapy candidate.